Research Themes

Health economics of melanoma and kidney disease


PhD, MScMed(Clin Epi)(Hons)

Prof Rachael Morton

Deputy Director

Professor Rachael Morton is Deputy Director of the CTC and also leads the Health Economics and Health Technology Assessment teams. She specialises in trial-based and modelled economic evaluation, patient reported outcome measures (PROMs) and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.


Research interests

  • Health economics of cancer and chronic diseases
  • Clinical trials
  • Health equity in disadvantaged populations both in Australia and overseas.
  • Patient reported outcome measures (PROMs)
  • Environmental impacts of healthcare
  • Measurement of quality of life and well-being


Teaching and supervision

Rachael coordinates short courses in health economics for government and industry and currently supervises five PhD candidates.



  • Within-trial and modelled economic evaluation
  • Preference elicitation
  • Outcomes assessment
  • Health equity
  • Chronic Kidney Disease
  • Melanoma and other cancers


Professional Associations

  • Board Director, Australian Clinical Trials Alliance (ACTA) member since 2016; Co-chair ACTA Reference Group – “Research Prioritisation: tools and criteria” since 2017
  • Past President, Health Services Research Association of Australia and New Zealand (HSRAANZ), member since 2011
  • Co-Convenor, Health Economists Alongside Trials (HEAT) special interest group with ACTA since 2020
  • Faculty Member, Melanoma Institute Australia, since 2017
  • Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Advisory Committee Member and Convenor, ANZDATA PROMs Working Group, since 2016
  • International Health Economics Association (IHEA) Program Chair 2018-2021, member since 2008
  • International Society for Pharmacoeconomic and Outcomes Research (ISPOR), member since 2009
  • Health Economists Study Group – UK (HESG) member since 2010
  • Cochrane Equity Methods Group member since 2013
  • Australia and New Zealand Society of Nephrology (ANZSN) member since 1996



View Rachael's publications.